Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Response

Journal Article

Full Text

Duke Authors

Cited Authors

  • Granger, CB; Mahaffey, KW; Weaver, WD; Theroux, P; Hochman, JS; Filloon, TG; Todaro, TG; Rollins, S; Mojcik, CF; Nicolau, JC; Ruzyllo, W; Armstrong, PW

Published Date

  • April 27, 2004

Published In

Volume / Issue

  • 109 / 16

Start / End Page

  • E195 - E196

International Standard Serial Number (ISSN)

  • 0009-7322